I Have Been Treating Eczema For Twelve Years. Last Year A Patient Asked Me A Question I Could Not Answer. This Is What I Found.

After seeing the same pattern in patient after patient, eczema and dry eyes, always together, always treated separately, I finally went back into the research. What I found had never made it into my training.

I want to start with something I find uncomfortable to admit.

I am a general practitioner with twelve years of experience. I have seen hundreds of patients with eczema. I have prescribed topical steroids, barrier creams, tacrolimus. I have referred dozens of patients to dermatology. I thought I knew eczema well.

Last spring, a patient named Claire sat across from me in my clinic. She was 31. She had moderate eczema, mostly on her forearms and around her eyes, and she had been my patient for four years. We had tried several approaches together and nothing had fully resolved it. There were always new patches, always something coming back.

She also mentioned, almost in passing, that her eyes had been dry for the past two years. She was using drops when needed. An optician had told her it was just dry eye and to continue with lubricating drops as required. She had accepted this the same way she had accepted the eczema. Something to manage.

"Do you think the two are connected?" she asked.

I paused. I gave her what I thought was a reasonable answer. Something about both being inflammatory in nature, possibly sharing some immune pathways. She listened carefully.

"But my optician does not know about my eczema," she said. "And my dermatologist does not know about my eyes. Is anyone actually looking at both at once?"

I did not have a good answer. And that bothered me enough that I went home that evening and started reading.

What I found over the following weeks changed how I practice. It is the reason I am writing this now.

The Pattern I Had Been Missing

Once I started looking, the pattern was everywhere in the research literature.

Patients with atopic dermatitis develop eye complications at a rate researchers estimate at between 25 and 40 percent. The condition has a clinical name: Atopic Keratoconjunctivitis. An inflammatory process affecting the conjunctiva and cornea, driven by the same immune dysregulation underlying the eczema on the skin. Same inflammation. Two locations.

I went back through my patient records. Over the previous three years, I had eight patients with diagnosed eczema. Five of them had mentioned dry eyes at some point in our consultations. I had noted it each time. I had not connected it. I had never asked whether the eye symptoms worsened around the same time as the skin.

Not once had I asked.

This is not a failure of individual doctors. It is structural. Specialisation means the patient moves between departments and the connecting thread is lost every time. The system was not built to see the whole person.

What The Research Actually Shows — And What I Was Never Taught

The skin and the surface of the eye share a fundamental requirement. Both depend on a protective lipid barrier built from two specific fatty acids: GLA, gamma-linolenic acid, and SDA, stearidonic acid.

GLA builds and maintains the skin's oil layer, the barrier that locks moisture in and keeps irritants out. The same fatty acid governs the production of the lipid film over the tear surface of the eye, the thin layer that prevents tears evaporating too quickly. SDA manages the inflammatory response in both locations, quieting the immune reaction when those barriers are challenged.

In most people, the body produces adequate GLA and SDA from dietary fats through an enzyme called delta-6 desaturase. This happens automatically. The barriers hold. You never think about either of them.

In many people with eczema, this conversion step does not work efficiently.

This was not in my medical training. Not because it is hidden. The research has been building since the 1980s, when David Horrobin first documented that eczema patients consistently showed reduced GLA metabolites in their blood. But nutritional biochemistry receives very little time in most medical curricula. It simply does not make it into clinical practice.

The result is that patients with a fatty acid conversion deficit are prescribed treatments that address the inflammation those deficits produce, while the deficit itself continues underneath everything, untouched.

Why Everything You Have Tried Only Ever Worked Partially

None of these are wrong. They address real aspects of real conditions. But they leave the conversion deficit, the actual root of the barrier failure in both skin and eyes, completely untouched.

What I Found When I Looked For Something That Actually Did Address It

The logical intervention is straightforward once you understand the mechanism. If the body cannot convert dietary fats into GLA and SDA efficiently, the solution is to provide GLA and SDA already formed, bypassing the conversion step entirely. Rather than supplying the raw material and relying on an enzyme that may not be working, you deliver what that enzyme was supposed to produce.

This approach has been tested in clinical trials.

The same fatty acids. Two separate conditions. Two separate randomised controlled trials. Both showing meaningful clinical improvement.

The challenge is that GLA and SDA are rarely found together in any supplement. Evening primrose and borage oil contain GLA but no SDA. Without SDA, the anti-inflammatory component of the mechanism is absent. You get partial improvement and continued reactivity. Finding a source that contains both, already formed, in a single formulation, that is what the research actually points toward and what has been largely missing from the market.

The Patients I Now Have A Different Conversation With

I want to be precise about who I am describing here. Not every eczema patient has a GLA conversion deficit. Eczema has multiple root causes. But for a specific pattern of patient, the evidence is much clearer.

For the patient who recognises that pattern, the GLA and SDA conversion deficit is the most evidence-supported explanation I have found. I now ask about dry eyes routinely when I see eczema patients. When both are present I explain the shared mechanism. The response I get most often is simply: why has nobody told me this before.

I do not have a satisfying answer. Only the honesty to say that I was one of the people who had not told them, and that I am trying to do better.

What I Pointed Claire Toward — And What Happened Six Months Later

After I understood the mechanism, the next question was practical. Where does someone actually get pre-formed GLA and SDA together, in a formulation that reflects what the research supports?

I spent time going through what was available. Most GLA supplements on the market contain GLA only. No SDA. A few contained GLA alongside supportive vitamins but not SDA. The combination the research pointed to was not easy to find as a complete formulation.

When I eventually found Calm Skin Capsule by Earth on Skin, I looked at the ingredient list carefully. GLA and SDA together, pre-formed from a natural plant source. Alongside that, anthocyanins for collagen and elastin support, Vitamin C for barrier repair and wound closure, Vitamin E for tissue regeneration, B6 for cellular-level inflammation suppression and melatonin production, B5 for new skin cell formation, B1 for the cellular energy the overnight repair cycle runs on.

Eight ingredients. Every one of them maps directly onto a documented aspect of what eczema-affected skin and a compromised tear film actually need. When you understand the mechanism, the formulation makes sense in a way that most supplements do not.